BioNTech’s Bold Leap Beyond COVID: The Great Pivot to Cancer Therapies
BioNTech is shifting focus from COVID-19 vaccines to pioneering mRNA-based cancer therapies amid falling vaccine profits. Projected revenues are decreasing, from 3.82 billion euros in 2023 to 1.7 to 2.2…